CanSino Biologics Inc: COVID-19 mRNA Vaccine

CanSino Biologics Inc: COVID-19 mRNA Vaccine

Vaccine Type: RNA

About Trial Phases

Phase 1: 1 Trial

NCT05373485
China

Phase 2: 1 Trial

NCT05373472
China

Phase 3: 1 Trial

NCT05442684

Approvals

This vaccine is not yet approved.

Registered Trials

NCT05442684
Phase 3
Total Enrollment: 1,350
Official Trial Registration:
- NCT05442684(Opens in new tab/window)
NCT05373472
Phase 2
China
Total Enrollment: 300
Official Trial Registration:
- NCT05373472(Opens in new tab/window)
NCT05373485
Phase 1
China
Total Enrollment: 80
Official Trial Registration:
- NCT05373485(Opens in new tab/window)

© 2022 VIPER Group COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form